XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Condensed Consolidated Statements of Stockholders’ Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Notes Due from  Affiliates
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Beginning balance (in shares) at Dec. 31, 2022   65,239,843        
Beginning balance at Dec. 31, 2022 $ 244,538 $ 67 $ 501,763 $ (314) $ (256,972) $ (6)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options (in shares)   185,073        
Exercise of stock options 714   714      
Vesting of restricted stock units (in shares)   870,915        
Vesting of restricted stock units 0 $ 1 (1)      
Taxes paid related to net settlement of equity awards (5,731)   (5,731)      
Repayment of notes due from affiliate 391   77 314    
Stock-based compensation expense 8,955   8,955      
Change in foreign currency translation adjustment 24         24
Net loss (14,071)       (14,071)  
Ending balance (in shares) at Mar. 31, 2023   66,295,831        
Ending balance at Mar. 31, 2023 234,820 $ 68 505,777 0 (271,043) 18
Beginning balance (in shares) at Dec. 31, 2022   65,239,843        
Beginning balance at Dec. 31, 2022 244,538 $ 67 501,763 (314) (256,972) (6)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Change in foreign currency translation adjustment 26          
Net loss (18,484)          
Ending balance (in shares) at Jun. 30, 2023   66,831,437        
Ending balance at Jun. 30, 2023 237,713 $ 68 513,081 0 (275,456) 20
Beginning balance (in shares) at Mar. 31, 2023   66,295,831        
Beginning balance at Mar. 31, 2023 234,820 $ 68 505,777 0 (271,043) 18
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options (in shares)   146,056        
Exercise of stock options 855   855      
Vesting of restricted stock units (in shares)   389,550        
Taxes paid related to net settlement of equity awards (2,820)   (2,820)      
Stock-based compensation expense 9,269   9,269      
Change in foreign currency translation adjustment 2         2
Net loss (4,413)       (4,413)  
Ending balance (in shares) at Jun. 30, 2023   66,831,437        
Ending balance at Jun. 30, 2023 $ 237,713 $ 68 513,081 $ 0 (275,456) 20
Beginning balance (in shares) at Dec. 31, 2023 68,155,830 68,155,830        
Beginning balance at Dec. 31, 2023 $ 247,064 $ 70 532,128   (285,143) 9
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options (in shares)   277,309        
Exercise of stock options 2,307   2,307      
Exercise of warrants (in shares)   41,685        
Exercise of warrants 94   94      
Vesting of restricted stock units (in shares)   965,238        
Vesting of restricted stock units 0 $ 1 (1)      
Taxes paid related to net settlement of equity awards (8,110)   (8,110)      
Stock-based compensation expense 8,261   8,261      
Change in foreign currency translation adjustment 1         1
Net loss (9,777)       (9,777)  
Ending balance (in shares) at Mar. 31, 2024   69,440,062        
Ending balance at Mar. 31, 2024 $ 239,840 $ 71 534,679   (294,920) 10
Beginning balance (in shares) at Dec. 31, 2023 68,155,830 68,155,830        
Beginning balance at Dec. 31, 2023 $ 247,064 $ 70 532,128   (285,143) 9
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options (in shares) 407,277          
Change in foreign currency translation adjustment $ (3)          
Net loss $ (20,741)          
Ending balance (in shares) at Jun. 30, 2024 74,132,201 74,132,201        
Ending balance at Jun. 30, 2024 $ 326,716 $ 74 632,520   (305,884) 6
Beginning balance (in shares) at Mar. 31, 2024   69,440,062        
Beginning balance at Mar. 31, 2024 239,840 $ 71 534,679   (294,920) 10
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options (in shares)   129,968        
Exercise of stock options 1,006   1,006      
Exercise of warrants (in shares)   88,212        
Exercise of warrants 1,055   1,055      
Vesting of restricted stock units (in shares)   428,378        
Taxes paid related to net settlement of equity awards (7,834)   (7,834)      
Stock-based compensation expense 11,159   11,159      
Settlement of convertible notes (in shares)   341,877        
Settlement of convertible notes 5,751   5,751      
Issuance of common stock net of underwriting discounts, commissions and issuance costs (in shares)   3,703,704        
Issuance of common stock net of underwriting discounts, commissions and issuance costs 86,707 $ 3 86,704      
Change in foreign currency translation adjustment (4)         (4)
Net loss $ (10,964)       (10,964)  
Ending balance (in shares) at Jun. 30, 2024 74,132,201 74,132,201        
Ending balance at Jun. 30, 2024 $ 326,716 $ 74 $ 632,520   $ (305,884) $ 6